Geron Corporation has enrolled the first patient in its Phase II clinical trial of imetelstat as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer.

The randomised, open label and multi-centric trial will test the effect of imetelstat on preventing or delaying tumour regrowth following debulking chemotherapy by targeting cancer stem cells.

The trial is designed to compare the efficacy maintenance treatment with imetelstat including standard of care against against standard of care alone in patients
with advanced non-small cell lung cancer who have not progressed after completing first-line induction chemotherapy.

Patients will be administered imetelstat at 9.4 mg/kg on days one and eight of a 21-day treatment cycle.

The primary efficacy endpoint for the trial will be the estimate of median progression-free survival for patients receiving imetelstat as maintenance therapy.

Secondary endpoints will be the objective response and time to all-cause mortality.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

An estimated 96 patients are to be enrolled from 20 clinical sites across the US for this clinical trial.